Австралия - английский - Department of Health (Therapeutic Goods Administration)

metagenics (aust) pty ltd - hypericum perforatum -

Израиль - английский - Ministry of Health

tzamal bio-pharma ltd - 5-aminolevulinic acid as hydrochloride - powder for solution - 5-aminolevulinic acid as hydrochloride 1.5 g - aminolevulinic acid - aminolevulinic acid - gliolan® is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (who grade iii and iv).

Израиль - английский - Ministry of Health

roche pharmaceuticals (israel) ltd - vemurafenib - film coated tablets - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.

Сингапур - английский - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus @ 100% - tablet, sugar coated - 2.0 mg - (active filler coat) sirolimus @ 100% 2.0 mg

Сингапур - английский - HSA (Health Sciences Authority)

pfizer private limited - sirolimus - solution - 1 mg/ml - sirolimus 1 mg/ml

Сингапур - английский - HSA (Health Sciences Authority)

pfizer private limited - (active filler coat) sirolimus @ 100% - tablet, sugar coated - 1.00 mg - (active filler coat) sirolimus @ 100% 1.00 mg

Европейский союз - английский - EMA (European Medicines Agency)

roche registration gmbh - vemurafenib - melanoma - antineoplastic agents - vemurafenib is indicated in monotherapy for the treatment of adult patients with braf-v600-mutation-positive unresectable or metastatic melanoma.,

Соединенные Штаты - английский - NLM (National Library of Medicine)

rebel distributors corp - indinavir sulfate (unii: 771h53976q) (indinavir - unii:5w6ya9pkkh) - indinavir 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

Соединенные Штаты - английский - NLM (National Library of Medicine)

state of florida doh central pharmacy - indinavir sulfate (unii: 771h53976q) (indinavir - unii:5w6ya9pkkh) - indinavir 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sirolimus, quantity: 0.5 mg - tablet, sugar coated - excipient ingredients: dl-alpha-tocopherol; iron oxide yellow; macrogol 8000; carnauba wax; iron oxide red; microcrystalline cellulose; purified talc; iron oxide black; povidone; magnesium stearate; macrogol 20000; shellac; sucrose; calcium sulfate; glyceryl monooleate; titanium dioxide; poloxamer; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; sulfuric acid - rapamune is indicated for the prophylaxis of organ rejection in patients at mild to moderate immunological risk receiving renal transplants. therapeutic drug monitoring of sirolimus is required.